AI Labs
Isomorphic Labs
An Alphabet-spun-out AI drug discovery company built on DeepMind's AlphaFold protein-structure technology, which raised a $2.1 billion Series B round in May 2026 led by Thrive Capital with participation from Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund. Isomorphic Labs holds multi-drug R&D alliances with Eli Lilly, Novartis, and Johnson & Johnson, and is targeting its first human clinical trials by late 2026.
Additional Intelligence Signals
Patent citation lineage, earnings-call mentions, and federal contract disclosures — automatically collected, not yet visible anywhere else on the site.
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
3 sources · 61% avg. source confidence
- BioSpace / PR Newswire — Isomorphic Labs raises $2.1B Series B to scale AI drug design engine74% source confidence
- Isomorphic Labs corporate site — Isomorphic Labs' pharma alliance portfolio spans Lilly, Novartis, and J&J60% source confidence
- pharmaphorum — Isomorphic Labs details use of Series B proceeds: clinical trials, international hiring48% source confidence
Dependency Map
What Isomorphic Labs depends on below, and who depends on Isomorphic Labs above — click any node to make it the new center, 3 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Isomorphic Labs's Timeline
A sourced, dated history of Isomorphic Labs's key moments — founding to present.
Jan 2021 · Spun out of Alphabet/DeepMind
Isomorphic Labs was spun out of Alphabet, building on DeepMind's AlphaFold protein-structure prediction technology to pursue AI-driven drug discovery.
May 2026 · $2.1B Series B round
Isomorphic Labs raised a $2.1 billion Series B round led by Thrive Capital, with participation from Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund, to scale its IsoDDE AI drug design engine and expand its therapeutic pipeline toward the clinic.